[1]彭巧丽,李美忠,蒋强,等.不同HIV-1病毒载量定量检测方
法的比较研究[J].中国艾滋病性病,2011,17(1):4-7.
[2]黑发欣,张启云,孙伟东,等.病毒载量检测有助于排除人免
疫缺陷病毒抗体可疑结果中的非感染者[J].中华预防医学杂
志,2008,42(1):43-46.
[3]Turner D, Wainberg MA. HIV transmission and primary drug
resistance [J].AIDS Rev,2006,8(1):17-23.
[4]李宁,孙定勇,马彦民,等.2008-2009年河南省新报告HIV
感染者和AIDS患者的死亡情况[J].中华预防医学杂志,
2010,44(11):999-1002.
[5]Vanittanakom N, Cooper CR Jr, Fisher MC,et a1. Penicilli?
um mameffei infection and recent advances in the epidemiology
and molecular biology aspects[J].Clin Microbiol Rev,2006,
19(1):95-110.
[6]黄爱琼,叶寒辉,吴秋芳,等.艾滋病合并马尔尼菲青霉菌感
染4例[J].中国艾滋病性病,2008,14(1):81.
[7]Fahey JL, Taylor JM, Manna B,et a1. Prognostic significance
of plasma markers of immune activation, HIV viral load and
CD4T-cell measurements[J].AIDS,1998,12(13):1581-1590.
[8]Katsoulidou A, Petrodaskalaki M, Sypsa V,et al. Evaluation
of the clinical sensitivity for the quantification of human immu?
nodeficiency virus type1RNA in plasma: Comparison of the
new COBAS TaqMan HIV-1with three current HIV-RNA
assays-- LCx HIV RNA quantitative, VERSANT HIV-1
RNA3.0(bDNA) and COBAS AMPLICOR HIV-1Monitor
v1.5[J].J VirolMethods,2006,131(2):168-174.
[9]Scott LE, Noble LD, Moloi J,et al. Evaluation of the abbott
m2000real time human immunodeficiency virus type 1(HIV-1) assay for HIV load monitoring in South Africa compared to
the roche cobas ampliprep-cobas amplicor, roche cobas am?
pliprep- cobas TaqMan HIV-1, and biomerieux nuclisens
easy Q HIV-1assays[J].J Clin Microbiol, 2009,47(7):
2209-2217.
[10]卫生部.全国艾滋病检测工作管理办法[EB/OL].
[2009-09-01].http://wwwl. china. com.cn/ Chinese/ PI-c/1256060.
htm.
[11]Porichis F, Kaufmann DE. HIV-specific CD4T cells and im?
mune control of viral replication[J].Curt Opin HIV AIDS,
2011,6(3):174-180.
[12]FreelSA, Saunders KO, Tomaras GD. CD8(+)T-cell-medi?
ated control of HIV-1and SIV infection[J].Immunol Res,
2011,49(1-3):135-146.
[13]van Bockel DJ, Price DA, Munier ML,et al. Persistent sur?
vival of prevalent clonotypes within an immunodominant HIV
gag-specific CD8+ T cell response[J].J Immunol,2011,
186(1):359-371.
[14]Xu S, Song A, Nie J, et al.Comparative evaluation ofthe CO?
BAS AmpliPrep/COBAS TaqMan HIV type1 test (CAP/
CTM) and VERSANT HIV type1RNA3.0assay (bDNA)
for quantifying HIV type1viral loads in China[J].AIDS Res
Hum Retroviruses,2008,24(11):1365-1373.
[15]Schumacher W, Frick E, Kauselmann M,et al. Fully auto?
mated quantification of human immunodeficiency virus (HIV)
type1RNA in human plasma by the COBAS AmpliPrep/CO?
BAS TaqMan system[J].J Clin Virol, 2007,38(4): 304-312.
[16]Piconi S, Trabattoni D, Gori A,et al. Immune activation,
apoptosis, and Treg activity are associated with persistently re?
duced CD4+ T-cell counts during antiretroviral therapy[J].
AIDS,2010,24(13):1991-2000.
[17]Heath SL, Sabbaj S, Bansal A,et al. CD8T-cell prolifera?
tive capacity is compromised in primary HIV-1infection [J].
J AcquirImmune Defic Syndr,2011,56(3):213-216.
[18]Jun H, Makoto I, HideyukiS.Identification ofcatalytic nucleo?
phile of Escherichia coliγ-glutamyltranspeptidase by mecha?
nism based affinity label[J].ICR Annual Report, 2000,7:
44-45.
[19]ChikhiN,HolicN,GuellaenG,etal.Gamma-glutamyl trans?
peptidase gene organization and expression:a comparative anal?
ysis in rat, mouse, pig and human species[J].Comp Bio?
chem PhysiolB Biochem MolBiol,1999,122(4):367-380.
[20]朱立华.实验诊断学[M].北京:北京医科大学出版社,
2002:355-356.
[21]王英,朱波,劳明,等.原发性肝癌患者血清酶类标志物变化
的临床意义[J].中国现代医学杂志,2011,21(4):521-523.
[22]王志有.原发性肝癌血清AFU AFP CHE及γ-GT酶联合检测
的分析[J].中国当代医学,2011,18(2):74-75.
[23]幺天保,龚兴荣,沈玲红,等.谷氨酰转移酶对急性ST段抬
高心肌梗死患者预后的预测价值[J].心脏杂志,2011,23
(1):95-99.
[24]于晓红,路聪哲.原发性胆汁性肝硬化与自身免疫性肝炎重叠
综合征合并药物性肝损伤1例[J].海军总医院学报,2006,
19(4):254-256.
[25]龙卉,衣京梅,李志斌,等.新生儿早期γ-谷氨酰转移酶水平
在新生儿黄疸诊疗中的意义[J].中国临床医生,2011,39
(4):49-51.
[26]朱燕,阿祥仁,刘庆春.脑梗死患者血清γ-谷氨酰基转移酶水平的观察[J].检验医学,2011,26(2):117-121.
[27]薛敏曦,魏祥松,张建敏,等.抗-HIV阳性者血清生化指标
分析[J].中华临床医学研究杂志,2005,1l(19):2862.
[28]潘光合,谭勇,吴文旺,等.出入境人群HIV感染者/AIDS患
者血清生化指标分析[J].旅行医学科学,2009,15(2):
4-7.
[29]陈宝敏,赵红心,李兴旺.核苷类逆转录酶抑制剂致获得性免
疫缺陷综合征乳酸酸中毒2例分析[J].中国实用内科杂志,
2009,29(9):868-869.
[30] John M, Moore C, James I,et al. Chronic hyperlactatemia in
HIV-infectedpatientstakingantiretroviraltherapy[J].AIDS,
2001,15(6):717-723.
[31]Bolhaar MG, Karstaedt AS. A high incidence of lactic acidosis
and symptomatic hyperlactatemia in women receiving highly
active antiretroviral therapy in Soweto, South Africa [J].
Clin InfectDis,2007,45(2):254-260.
[32]Geddes R1, Knight S, Moosa MY,et al. A high incidence of
nucleoside reverse transcriptase inhibitor (NRTI)-induced lac?
tic acidosis in HIV-infected patients in a South African context
[J].S AfrMed J,2006,96(8):722-724.
[33]Claessens YE, Chiche JD, Mira JP,et al. Bench-to-bedside
review: severe lactic acidosis in HIV patients treated with nu?
cleoside analogue reverse transcriptase inhibitors[J].Crit?
Care,2003,7(3):226-232.